Glucose‐lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 554-559

John Wiley & Sons Inc

Access to resources Recommend Favorite

Insulin lispro protamine suspension in intensive insulin treatment: an Italian observational study

By Citro Giuseppe   Lorusso Bruna   Rossi Andrea   Romaniello Marianna   Gentilella Raffaella   Cremasco Francesco  

Current Medical Research and Opinion, Vol. 25, Iss. 9, 2009-09 ,pp. : 2259-2265

Informa Healthcare

Access to resources Recommend Favorite

Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus

By  

PEDIATRIC DIABETES (ELECTRONIC), Vol. 16, Iss. 5, 2015-08 ,pp. : 361-366

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis*

By Tunis Sandra L.   Minshall Michael E.   Conner Christopher   McCormick John I.   Kapor Jovana   Yale Jean-François   Groleau Danielle  

Current Medical Research and Opinion, Vol. 25, Iss. 5, 2009-05 ,pp. : 1273-1284

Informa Healthcare

Access to resources Recommend Favorite

The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis

By Currie Craig J.   Poole Chris D.   Tetlow Tony   Holmes Paul   McEwan Phil  

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-02 ,pp. : 33-39

Informa Healthcare

Access to resources Recommend Favorite